These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436 [TBL] [Abstract][Full Text] [Related]
26. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Irie T; Tsujii M; Tsuji S; Yoshio T; Ishii S; Shinzaki S; Egawa S; Kakiuchi Y; Nishida T; Yasumaru M; Iijima H; Murata H; Takehara T; Kawano S; Hayashi N Int J Cancer; 2007 Aug; 121(4):878-83. PubMed ID: 17450522 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Badawi AF; Eldeen MB; Liu Y; Ross EA; Badr MZ Cancer Res; 2004 Feb; 64(3):1181-9. PubMed ID: 14871855 [TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Wang YX; Gao JX; Wang XY; Zhang L; Liu CM Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523 [TBL] [Abstract][Full Text] [Related]
29. Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells. Parajuli P; Tiwari RV; Sylvester PW Cell Prolif; 2015 Aug; 48(4):421-35. PubMed ID: 26096843 [TBL] [Abstract][Full Text] [Related]
30. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Chen L; He Y; Huang H; Liao H; Wei W Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786 [TBL] [Abstract][Full Text] [Related]
31. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692 [TBL] [Abstract][Full Text] [Related]
32. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. Sylvester PW; Shah S Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643 [TBL] [Abstract][Full Text] [Related]
33. Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Yang Z; Xiao H; Jin H; Koo PT; Tsang DJ; Yang CS Int J Cancer; 2010 Feb; 126(4):852-63. PubMed ID: 19626588 [TBL] [Abstract][Full Text] [Related]
34. Enhancement of apoptotic activities on brain cancer cells via the combination of γ-tocotrienol and jerantinine A. Abubakar IB; Lim KH; Kam TS; Loh HS Phytomedicine; 2017 Jul; 30():74-84. PubMed ID: 28545672 [TBL] [Abstract][Full Text] [Related]
35. Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. Ferrario A; Lim S; Xu F; Luna M; Gaffney KJ; Petasis NA; Schönthal AH; Gomer CJ Cancer Lett; 2011 May; 304(1):33-40. PubMed ID: 21339042 [TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357 [TBL] [Abstract][Full Text] [Related]
37. Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Liu B; Wen JK; Li BH; Fang XM; Wang JJ; Zhang YP; Shi CJ; Zhang DQ; Han M Cell Death Dis; 2011 Jul; 2(7):e185. PubMed ID: 21796157 [TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Zhang GS; Liu DS; Dai CW; Li RJ Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520 [TBL] [Abstract][Full Text] [Related]
39. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230 [TBL] [Abstract][Full Text] [Related]
40. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]